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AbstrAct
AXL is a tyrosine kinase receptor activated by GAS6 and regulates cancer cell 
proliferation migration and angiogenesis. We studied AXL as new therapeutic target 
in colorectal cancer (CRC). Expression and activation of AXL and GAS6 were evaluated 
in a panel of human CRC cell lines. AXL gene silencing or pharmacologic inhibition 
with foretinib suppressed proliferation, migration and survival in CRC cells. In an 
orthotopic colon model of human HCT116 CRC cells overexpressing AXL, foretinib 
treatment caused significant inhibition of tumour growth and peritoneal metastatic 
spreading. AXL and GAS6 overexpression by immunohistochemistry (IHC) were found 
in 76,7% and 73.5%, respectively, of 223 human CRC specimens, correlating with less 
differentiated histological grading. GAS6 overexpression was associated with nodes 
involvement and tumour stage. AXL gene was found amplified by Fluorescence in situ 
hybridization (FISH) in 8/146 cases (5,4%) of CRC samples. 
Taken together, AXL inhibition could represent a novel therapeutic approach in 
CRC. 
IntroductIon
Colorectal cancer (CRC) is a prominent global 
health problem, representing the third most common 
cancer worldwide [1]. Metastatic CRC (mCRC) occurs 
in about 25% of patients at diagnosis [2] and it is a not 
curable disease in approximately 25-30% of patients, 
following treatment of locoregional disease; several 
chemotherapeutics agents including irinotecan, oxaliplatin 
and more recently targeted monoclonal agents, such as 
cetuximab, panitumumab, bevacizumab and regorafenib 
contributed to extend the survival of these patients [3-5]. 
However, resistance to both chemotherapy and molecular 
targeted agents might occur [6]. Identification of resistance 
mechanisms and activation of alternative pathways are 
crucial for improving therapeutic efficacy.
AXL is a member of the TAM (TYRO3, AXL, 
MER) receptor tyrosine kinase (RTK) family [7,8]. The 
primary ligand for TAM receptors is Growth Arrest-
Specific 6 (GAS6), a fairly large (75 kDa), vitamin 
Oncotarget23282www.impactjournals.com/oncotarget
table 1: common up-regulated genes in AXL expressing crc cell lines. 
GEnE sYMboL GEnE nAME FoLd cHAnGE
ADAM11 ADAM metallopeptidase domain 11 10,7943
AHNAK2 AHNAK nucleoprotein 2 7,985296
AKT3 v-akt murine thymoma viral oncogene homolog 3 12,12195
BCL2 B-cell CLL/lymphoma 2 9,289825
BMP6 bone morphogenetic protein 6 54,55846
BMP7 bone morphogenetic protein 7 66,8874
BMP8A bone morphogenetic protein 8a 26,31088
BMP8B bone morphogenetic protein 8b 8,796837
CALD1 caldesmon 1 103,4702
CAV2 caveolin 2 4,0217
COL3A1 collagen, type III, alpha 1 16,79685
FLT1 fms-related tyrosine kinase 1 11,51779
FN1 fibronectin 1 18,60154
GLI1 GLI family zinc finger 1 8,795941
GLI2 GLI family zinc finger 2 9,151444
GLI3 GLI family zinc finger 3 7,520125
MITF microphthalmia-associated transcription factor 11,63769
MSN moesin 92,42856
NRG1 neuregulin 1 25,02382
SMO smoothened, frizzled family receptor 94,62124
SNAI3 snail homolog 3 (Drosophila) 4,282289
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 48,42324
TCF4 transcription factor 4 12,59067
TGFB1 transforming growth factor, beta 1 5,194356
TGFB1I1 transforming growth factor beta 1 induced transcript 1 4,151411
TGFB2 transforming growth factor, beta 2 8,969274
TMEFF1 transmembrane protein with EGF-like two follistatin-like domains 1 4,351279
TMEM132A transmembrane protein 132A 4,58216
TWIST1 twist homolog 1 (Drosophila) 6,788473
VCAN versican 10,09725
VIM vimentin 13,15245
WNT5A wingless-type MMTV integration site family, member 5A 25,32227
ZEB1 zinc finger E-box binding homeobox 1 4,082564
Microarray gene expression analysis was performed in CRC cell lines expressing AXL and CRC cell lines defined 
as AXL negative. Using the Student’s t test with Benjamini–Hochberg multiple test correction, 1553 and 1061 genes 
were identified as up-regulated or down-regulated, respectively, in AXL positive CRC cells (t test, P < 0,05). Among 
the up-regulated genes we identify 33 genes involved in epithelial to mesenchymal transition (EMT) listed in the 
table.
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K–dependent protein, known to activate downstream 
signalling [9]. Binding of GAS6 to the extracellular 
domain of AXL leads to dimerization of GAS6–AXL 
complexes. The latter results in autophosphorylation of 
tyrosine residues (Tyr779, Tyr821 and Tyr866) in the 
intracellular tyrosine kinase domain [9]. 
AXL is overexpressed in several human cancers, 
including various leukemias and solid tumours, where 
it is associated with a poor prognosis [10-17]. For these 
reasons, we examined the potential biological relevance 
of AXL pathway activation and its inhibition in CRC 
preclinical models and AXL and GAS6 expression in 
human CRC specimens. 
rEsuLts
Expression and activation of AXL in human 
colorectal cancer cell lines
We first performed a screening with a receptor 
tyrosine kinase array in four human CRC cell lines 
(SW620, SW480, LOVO, HCT116) non-responsive to the 
anti-EGFR targeting drugs, as they harbour mutations in 
KRAS genes [18-22]. Among several receptors involved 
in CRC tumorigenesis, AXL phospho-protein was 
found in all four human CRC cell lines (Figure 1A). As 
illustrated in Figure 1B, AXL protein expression was also 
confirmed in SW620, SW480, LOVO, HCT116, whereas 
no expression was found in the remaining cells: SW48, 
Figure 1: Expression and activation of AXL in human crc cell lines. A. 300 µg of protein lysates were obtained from human 
CRC cell lines SW620, SW480, LOVO, HCT116 and were analysed by human phospho-kinase array evaluating the following receptors: 
AXL, EphA1, EphA2, EphA3, EphA6, EphA4, EphA7, EphB1 EphB2, EphB4, EphB6, ErbB2, ErbB3, ErbB4, EGFR, FGF R1, FGFR2a, 
FGF R3, FGFR4, Flt 3, HGF R, insulinR, IGF-I R, Mer, MSPR, MCSFR, MuSK, PDGFrα, PDGrβ, SCFR, cRET, ROR1, ROR2, Tie2, 
TrkA, TrkB, TrkC, VEGFR1, VEGFR2, VEGFR3, Tie1. b. Western blot analysis of AXL receptor in SW48, SW48-CR, HT29, LOVO, 
SW620, HCT15, HCT116, GEO, GEO-CR, COLO205, SW480. Thirty micrograms of cell protein extracts were fractionated through 4% 
to 20% SDS-PAGE, transferred to nitrocellulose filters, and incubated with the indicated antibodies as described in Materials and Methods. 
Immunoreactive proteins were visualized by enhanced chemiluminescence. c. specific mRNA expression by quantitative real time-PCR: 
total RNA was extracted from colorectal (SW620, SW48, SW480, HT29, LOVO, HCT15, HCT116) and thyroid cancer cell lines (TPC, 
CAL 62) quantitative real time-PCR was done to assess the expression of AXL and GAS6 mRNA. d. GAS6 protein levels were measured 
in cell culture media of CRC cancer (SW620, SW48, SW480, HT29, LOVO, HCT15, HCT116) and thyroid (TPC, NIM) cancer cell lines 
by using specific ELISA as described in Materials and Methods. 
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HT29, HCT15, GEO, COLO205, GEO-CR and SW48-
CR, these two latter cell lines present acquired resistance 
to cetuximab [23]. AXL and its ligand GAS6 mRNA were 
also screened by real time-PCR (RT-PCR) using TPC1 
and CAL62, two thyroid cancer cell lines, as positive 
controls. AXL mRNA was detected at variable levels 
ranging between 1 and 238,8 fold as compared with TPC1 
and CAL62 in the cell lines tested, being barely detected 
in SW48, HT129 and HCT15. GAS6 mRNA was weakly 
found in all CRC cell lines (range 1-14,9) (Figure 1C). 
We analysed the secretion of GAS6 into the cell 
culture media (CM). Forty-eight hours (hrs) after cell 
seeding, cancer cells were serum starved and collected 
after additional 24 hrs. As shown in Figure 1D, GAS6 was 
secreted only by thyroid cancer cells (NIM) that were used 
as a positive control (Figure 1D), suggesting a ligand-
independent activation of AXL in human CRC cells.
In order to identify genes or pathways related with 
AXL expression, we analysed baseline microarray gene 
expression of CRC cell lines expressing AXL compared 
to CRC cell lines defined as AXL negative. In this respect, 
we found 1553 and 1061 genes defined as up-regulated 
or down-regulated, respectively, in AXL positive cancer 
cell lines (t test, p < 0.05) (data not shown). Among the 
up-regulated genes, 33 genes are involved in epithelial to 
mesenchymal transition (EMT) (Table 1). 
AXL blockade inhibits colorectal cancer cell 
proliferation and survival
Inhibition of AXL might be a novel therapeutic 
approach to treat CRC. Therefore, we evaluated the effects 
on cell growth proliferation of foretinib, which is an oral 
multikinase inhibitor of c-MET and VEGFR2 and that 
was recently described as a potent inhibitor of AXL [24]. 
We tested treatment with foretinib in HCT116, SW480, 
SW620, LOVO, HCT15, HT29 and SW48. Cancer cells 
Figure 2: Effects of AXL blockade on crc cancer cell proliferation and survival. A. Effects of foretinib on cell proliferation 
in the panel of human CRC cell lines. As described in Materials and Methods, cancer cells were treated for 72 hrs with increasing 
concentration of foretinib (0.01–10 µM) and evaluated for proliferation by MTT staining. The results are average ± SD of three independent 
experiments each done in triplicate. b. Analysis of intracellular signalling pathways by Western blot in SW620, LOVO, HCT116, SW48 
cancer cells treated with foretinib at indicated doses for 2 and 24 hrs. Total cell protein extracts (30 µg) were subjected to immunoblotting 
with the indicated antibodies as described in Materials and Methods. c. HCT116, LOVO and SW620 cancer cell lines were transfected with 
100 nmol/L AXL siRNA for 72h evaluated for proliferation by MTT staining. d. 30 µg of protein lysates derived from HCT116, LOVO 
and SW620 AXL siRNA were extracted and analysis of intracellular signalling pathways with the indicated antibodies was performed by 
Western blot as described in Materials and Methods.
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were treated with foretinib at dose concentrations ranging 
from 0.1 to 10 μM for 72 hr. The drug concentrations 
required to inhibit cell growth by 50% (IC50) were 
determined by interpolation from the dose-response 
curves. As shown in Figure 2A IC50 values ranging 
between 1 μM and > 5 μM. The most sensitive cells to 
foretinib were HCT116 and SW620 (IC501μM) whereas 
the most resistant were HT29 and SW48 cells with little 
or no growth inhibition even up to 10μM concentration of 
the drug. 
To determine the inhibition of intracellular signals 
for cell survival and proliferation, Western blot analysis 
were performed on protein extracts derived from SW620, 
LOVO, HCT116 and SW48 cancer cells, treated with 
foretinib (2μM) for 2 and 24 hrs. Foretinib treatment 
decreased the levels of active phosphorylated AXL 
(pAXL) and its downstream pathway in SW620, LOVO 
and HCT116 cells (Figure 2B).
To further evaluate AXL inhibition effects, we used a 
RNA interference approach. LOVO, HCT116 and SW620 
human CRC cells were transfected with AXL specifics 
siRNAs. AXL silencing was verified by Western blot. 
AXL knockdown correlated with a significant inhibition 
of proliferation evaluated by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) in HCT116, 
LOVO and SW480 of 78% and 68%, respectively (p < 
0.001) (Figure 3C). Moreover, seventy-two hrs after AXL 
silencing, a reduction of 5-bromo-2-deoxyuridine (BrdU) 
incorporation of 70 % was observed (data not shown). 
Inhibition of AXL gene expression was also accompanied 
by a reduction of phosphoERK (pERK), phosphoAKT 
(pAKT) and phospho ribosomal protein S6, 24, 48 and 72 
hrs after AXL silencing, (Figure 2D).
biological effects of AXL gene stable inhibition in 
LoVo human colorectal cells
We stably transfected LOVO CRC cells with a pool 
of vectors expressing 5 different shRNAs directed against 
AXL or expressing control non-targeting shRNAs. Stable 
transfectants were selected and amplified in medium with 
500ng/mL puromycin for 12 weeks. We identified clones 
(Figure 3A) that expressed intermediate (shAXLCl 3) or 
low (shAXLCl 1,5 and 8) AXL levels (Figure 3B). We 
tried also to establish HCT116 stable transfectants but 
HCT116 were not able to survive after AXL knockdown, 
suggesting AXL relevant role in HCT116 cell survival 
(data not shown). In shAXL1,3,5,8 clones, the activation 
of the MAPK and PI3K pathways (pAKT and of pS6 
ribosomal protein) were decreased with respect to control 
(sh-AXL pool and sh-CTR) or parental cells (Figure 3B). 
Furthermore, E-cadherin levels were slightly increased in 
shAXL 1,3,5,8 clones, indirectly suggesting that AXL is a 
marker of EMT (Figure 3B).
We verified whether AXL knockdown could inhibit 
cell growth. AXL silencing showed a statistical significant 
suppression of cell growth in sh-Cl1 and 3 (p < 0.05) 
(Figure 3C). We also performed the trypan blue exclusion 
viability assay and we verified that sh-AXL clones did not 
showed any trypan blue staining, suggesting a delay of cell 
growth rather then cell death (data not shown). 
 To investigate the role of AXL in CRC cell 
migration we used transwell cell culture chambers. ShAXL 
clones (Cl1, 3 and 5) showed a clear decrease of invasive 
ability with respect to shCTR cells after 24 hrs. These data 
confirm that AXL is an important mediator of migration 
and invasion in these CRC cells (Figure 3D).
Pharmacologic inhibition of AXL signalling 
activation with foretinib in a human colorectal 
cancer orthotopic xenograft model
We further investigated the in vivo antitumor activity 
of foretinib. We developed a colon orthotropic model of 
human HCT116 cells in nude mice. We did not use LOVO 
AXL knockdown clones for in vivo experiments because 
of their low rate of proliferation that could affect sub-
cutaneous growth. 
Briefly, a total of 2 X 106 HCT116 cells re-suspended 
in 200 µl of matrigel and PBS (1:1) were implanted 
subcutaneously into the right flank of nude female mice. 
When the average tumours reached a mean volume of 500 
mm3 animals were euthanized, the tumours were removed 
and divided into 2-3 mm-sized pieces and harvested in 
PBS. Mice were treated with antibiotics, ticarcillin (50
mg kg−1i.v.), two hrs before and after tumour implantation 
(for more details refer to Materials and Methods). After 
10 days from the orthotopic implantation of tumour in to 
cecum wall of the mice, foretinib treatment was started 
(15mg/kg) per os 5 days a week for three weeks. As 
shown in Figure 4A and Table 2, the control group mice 
had large tumours in cecum with a 100% incidence of 
regional lymph nodes and peritoneal metastasis, showing, 
furthermore, worst clinical conditions and weight loss. 
In particular, in the control arm the mean weight was 
statistically lower compared to the treatment arm (20,5 
gr versus 23,5 gr; p < 0.0001) (Table 2). In the foretinib 
treated arm, the necropsy of mice revealed no evidence 
of peritoneal disease and metastasis in visceral organs 
(intestine, rectum, liver, spleen and lung) (Figure 4A). 
We performed a Western blot analysis for the expression 
of AXL and the activated downstream pathways in the 
tumours: pAXL, pAKT and pS6 ribosomal protein levels 
were decreased in foretinib treated mice. No evident effect 
on ERK phosphorylation was observed (Figure 4B).
Finally, in mice treated with foretinib, tumour 
growth was significantly (p < 0 0.0001) decreased 
compared with the control group, with a complete 
response (defined as the absence of tumour at necropsy) 
evidenced in one mouse (Figure 4C). Foretinib treatment 
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was well tolerated by mice, with no signs of acute or 
delayed toxicity.
Expression of AXL and GAs6 proteins in human 
colorectal cancer and AXL gene amplification
We evaluated whether AXL and its ligand GAS6 
were expressed in CRC specimens. A total of 223 
patients diagnosed with CRC were included. Baseline 
clinicopathological characteristics of patients are 
summarized in Table 3. The median follow up time was 
39.5 months.
AXL protein expression by immunohistochemistry 
(IHC) was detected in 171 out of 223 tumour specimens 
(76.7%) whereas AXL expression was undetectable in 
52 out of 223 (23.3%) (Figure 5A, Figure 5B,a). Among 
AXL positive cases, 111 (65%) showed high expression 
levels (staining in ≥20% cancer cells), whereas 35% 
showed low expression (staining in < 20% cancer cells) 
(Figure 5A). AXL staining mostly displayed membrane 
positivity; in a small number of cases cytosolic staining 
was observed and in one specimen nuclear staining was 
detected. Tumoral stroma and non-tumoral adjacent tissues 
were AXL negative, 10% of cases had endothelial cells 
positivity. Colon normal tissue did not express AXL (data 
not shown).
We further examined AXL intensity expression 
pattern. Ninety-five percent of positive specimens 
showed an incomplete baso-lateral membranous pattern. 
The remaining cases were characterized by a complete 
intensity pattern; 76 cases were scored as low (1+) (Figure 
5B,b), 90 cases as moderate (2+) (Figure 5B,c), 5 cases 
as high (3+) (Figure 5B,d). A significant correlation (p 
< 0.0001) between cancer cell percentage staining and 
intensity expression levels was found. 
Figure 3: Effects of AXL gene stable silencing in LoVo crc cells. A. Stable transfected LOVO CRC cells with a pool of vectors 
expressing 5 different shRNAs directed against AXL or expressing control non targeting shRNAs. Four shAXL clones were identified. b. 
Analysis of intracellular signalling pathways by Western blot in shAXL clones (Cl1,3,8). Total cell protein extracts (30 µg) were subjected 
to immunoblotting with the indicated antibodies as described in Materials and Methods. c. cell growth curves of shAXL clones; 50.000 
cells of sh-CTR, sh-AXL pool, shAXL 1,3,5,8 clones were seeded on day 0 and the total number of cells was counted every day until day 
4. Every day detached cells were stained with Trypan blue 0,4%, and nonviable blue-stained cells were counted. Each point represents the 
mean value of 3 culture dishes, *p < 0.05. d. migration assay of shAXL CRT,1,3,5 clones shAXL 1,3,5,8 after 24 hrs.
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table 2: Mice tumour diameter and weight, mice weight in control and foretinib groups.
control tumour diameter
(cm) 
tumour weight 
(gr)
Mouse weight
(gr)
1 3,1X3,2 5,1 17
2 3X3 5,1 21,3
3 2,3X2 2,8 17,7
4 3X3 4,9 21,8
5 3,1X2,8 5 20,3
6 3,3X2,9 4,8 22
7 3X2,7 4,9 21,7
8 2,9X2,8 4,7 22
Foretinib 
9 1,8X1,5 2 17
10 1,6X1,5 3,6 22,5
11 0,2X0,2 0 26,7
12 1,8X1,6 1,2 22,3
13 1,8X1,3 1,3 24,3
14 1,2X1 0,5 29,1
15 1,9X1,7 2,1 21,3
16 1,8X1,5 2,2 23
HCT116 subcutaneous tumour xenografts were implanted in to the cecal wall of mice. After 
one week mice were randomized and divided in two different groups and treated with vehicle 
or foretinib at the dose of 15mg/kg (oral gavage once a day) for 3 weeks (5 days a week). 
Mice tumour diameter , tumour  weight and mice weight (p<0.0001) are indicated in the table.
Figure 4: Foretinib inhibits growth of Hct116 crc orthotopic xenograft models. HCT116 subcutaneous tumour xenografts 
were implanted in to the cecal wall of mice. After one week mice were randomized and divided in two different groups and treated with 
vehicle or foretinib at the dose of 15mg/kg (oral gavage once a day) for 3 weeks (5 days a week). Animals were sacrificed 1 week after 
stopping treatment. A. Tumour incidence and presence of visceral metastasis. b. Western blot analysis of intracellular signalling pathways 
in mice treated with foretinib and in the control arm. Total cell protein extracts (30µg) were subjected to immunoblotting with the indicated 
antibodies as described in Materials and Methods. c. Tumour volume (mm3) of control and treated mice are compared. Each group 
consisted of 8 mice. ***p < 0.0001
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Since AXL was overexpressed in approximately 2/3 
of AXL positive cases, we evaluated if gene amplification 
could occur. Fluorescence in situ hybridization (FISH) 
analysis was performed in 146 AXL positive specimens. 
Eight cases (5.4%) showed AXL gene amplification 
(Figure 5C,b) with AXL/CEP19 ratio ranging from 2 
to 2.5, whereas 138 cases (94.6%) were FISH negative 
(Figure 5C,a). A high significant correlation between 
AXL protein expression levels and gene amplification was 
observed (p < 0.0001). Within the 8 AXL gene amplified 
specimens, high intense (3+) AXL protein expression 
was found in 2 cases, AXL moderate intensity expression 
pattern (2+) was detected in the other 6 cases. No cases 
with AXL low intense (1+) were found FISH positive 
(Figure 5D). 
Furthermore, we analysed GAS6 expression levels 
in the same specimens. We found 164 out 223 cases 
(73.5%) that stained positively (Figure 5A), whereas 59 
cases (26.5%) were negative for GAS6 expression (Figure 
5A,B,e). Within the positive specimens, 52 (32%) were 
classified as low expression (staining in < 20% cancer 
cell), 112 as high expression (staining in ≥20% cancer 
table 3: demographic distribution of patients for the 
total study population. 
characteristics n=223(%)
Age (yr)
Median 59
Range 29-80
Sex
Male 130
Female 93
Site of primary 
Tumor
Right colon 97 (43,5)
Left colon or
rectum
126 (56,5)
Grading
G1 7 (3,1)
G2 179 (80,3)
G3 37 (16,6)
Tumor
T1 10 (4,5)
T2 61 (27,4)
T3 129 (57,8)
T4 23 (10,3)
Lymph node status
N0 93 (41,7)
N1 65 (29,1)
N2 65 (29,1)
Localized 152 (68,2)
Metastatic 71 (31,8)
Histological blocks of 223 patients diagnosed with CRC 
undergone to surgical resection treatment between 2003 
and 2011 were selected. Patient’s clinic-pathologic 
characteristics are listed in the table.
Figure 5: Expression of AXL and GAs6 proteins in human colorectal cancer. A. Distribution of AXL and GAS6 expression (% 
of cells staining) measured by using IHC in all available CRC patients (left part). b. representative figures of AXL and GAS6 IHC status in 
the study population. Different staining intensities (40 x original magnification) in AXL negative (a), low (b), moderate (c), high (d) intense 
AXL positive tumour tissues and GAS6 negative (e) and positive (f) specimens. c. Representative figures of AXL gene status (red-orange 
signal) and CEN 19q (green signal) measured by using FISH in a small cohort of tumour cases (N = 146), (a) non amplified sample, AXL/
CEP19 ratio:1 (b) amplified sample , harbouring AXL gene amplification, AXL/CEP19 ≥ 2. d. correlation between AXL IHC expression 
and FISH analysis; IHC and FISH analysis were described in Materials and Methods, ***p < 0.0001(Pearson chi-square test).
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cell) (Figure 5A, bottom part).
GAS6 showed a iuxtamembranous staining, 10% 
of cases displayed stromal positivity, indicating that the 
ligand can be provided by tumour microenvironment. 
A significant statistical correlation between AXL and 
GAS6 expression was found (p < 0.0001) (Figure 6A). 
To investigate the clinical relevance of AXL and GAS6 
status, we evaluated the association between patients 
clinicopathological features and their expression levels. 
Neither AXL nor GAS6 were associated with age, sex, 
tumour primary location, tumour depth and presence of 
distant metastasis at initial diagnosis (p > 0.05; data not 
shown). Both AXL and GAS6 expression levels were 
correlated with histological grading (p < 0.05; Figure 
6B) resulting markedly expressed in less differentiated 
specimens. GAS6 but not AXL was associated with lymph 
nodes status (p < 0.05; Figure 6B) and consequently with 
tumour stage (p < 0.05) showing a higher expression in 
more advanced disease (data not shown).
To evaluate the prognostic significance of AXL and 
Figure 6: AXL and GAs6 clinicopathological features correlation and prognostic relevance. A. correlation between AXL 
(% of cells staining and HSCORE) and GAS6 expression levels, by using Pearson correlation coefficient. b. correlation between AXL 
expression levels (% of cells staining) and grading and GAS6 expression levels with grading and lymph nodes status by using non-
parametric Mann-Whitney U test and Kruskal-Wallis test when indicated. c. univariate analysis of overall survival (Kaplan-Meier method) 
in CRC patients data-set using the Log-rank (Mantel-Cox) statistical test stratify by AXL and GAS6 expression.
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GAS6 expression, survival analysis was performed by 
using Log-rank (Mantel-Cox) statistical test. In the AXL 
negative patients population median Overall Survival (OS) 
was 55.2 months (95% CI 41.5-68.9); in AXL-positive 
low expression patients, OS was 51.8 months (30.6-73.1) 
whereas in AXL-positive high expression patients, OS 
was 59.2 months (95% CI 43.8-74.5). AXL expression 
was not prognostic in our CRC dataset (p > 0.05; Figure 
6C). In GAS6 negative patient population the median 
OS was 55.8 months (95% CI 46.9 - 64.7); among the 
GAS6-positive subgroups classified as low expression, 
OS was 74.6 months (95% CI 55.8 - 93.5), in GAS6-
positive high expression, OS was 59.6 months (95% CI 
48.0 - 71.2). GAS6 had no apparent impact on survival 
(Figure 6C). Similar data were obtained with HSCORE 
(refer to Materials and Methods for details) values (p > 
0.05) and AXL intensity expression levels (p > 0.05) (data 
not shown).
dIscussIon
Colorectal cancer is a complex heterogeneous 
disease with defined subtypes based on different gene 
expression profıles. Efforts have been made to find a 
“consensus” subtypes classification useful to tailor therapy 
for CRC patients. According to gene expression profiles 
and genomic characterization, recently, at least three CRC 
subgroups have been proposed: microsatellite instability 
(MSI), chromosomal instability (CIN) epithelial/
proliferative and CIN mesenchymal/invasive phenotype 
[25].
Critical genes and pathways important in the 
initiation and progression include the WNT, RAS, MAPK, 
PI3K, TGFβ, p53 and DNA mismatch-repair pathways 
that, when genetically altered, negatively impact on drug 
antitumor activity. Examples include the lack of benefıt of 
anti-EGFR monoclonal antibodies (moAbs) in presence 
of RAS mutation [22]. Moreover, recently it has been 
described that MET or HER2 gene amplification could be 
involved in primary and acquired resistance mechanisms 
to anti-EGFR moAbs [21,23].
In this scenario, AXL receptor might be considered 
a novel potential target as its overexpression has been 
reported in a variety of human cancers and it has been 
associated with worse prognosis [10-17, 26].
To investigate the role of AXL in cancer 
progression we used a panel of human CRC cell lines 
were we detected AXL protein expression and activation. 
Inhibiting AXL pathway by using specific silencing 
RNA or a pharmacologic approach with foretinib, we 
demonstrated that cancer cell proliferation and migration 
was significantly suppressed. We further developed, in our 
laboratory, a model of human colon orthotopic xenograft 
nude mice, to evaluate the pharmacological inhibition of 
AXL activation. Foretinib treatment caused significant 
inhibition of tumour growth and peritoneal metastatic 
spreading compared with untreated controls confirming 
the in vitro findings. 
The preclinical findings described in our manuscript 
demonstrated that the antitumor activity obtained by 
AXL inhibition is clinical relevant, because all human 
CRC cell lines used do not respond to the common anti-
EGFR moAb due to KRAS mutations that confer primary 
resistance to these agents. In this respect, several studies 
suggest that overexpression of AXL may be implicated 
in resistance to both targeted therapies and conventional 
chemotherapy in different cancer models [7, 27]. In 
a recent study it has been reported that in cellular lung 
cancer models of acquired resistance to the EGFR TKI 
erlotinib there was an increased activation of AXL and 
induction of an EMT-like state [28-29]. Furthermore, 
Brand and colleagues demonstrated that AXL is involved 
in acquired resistance to cetuximab in models of head and 
neck squamous cell carcinoma (HNSCC), in which it was 
overexpressed, activated and tightly associated with EGFR 
expression in cancer cells resistant to cetuximab [30].
However, in the present study we did not find AXL 
pathway activation in two models of acquired resistance 
to anti-EGFR antibodies cetuximab (GEO-CR and SW48-
CR) that were generated in our laboratory. As a possible 
explanation, in these two CRC cell lines (GEO-CR and 
SW48-CR) acquired resistance to cetuximab was meanly 
due to TGFα mediated heterodimerization of MET with 
EGFR [23] and by activation of angiogenesis [31].
EMT is a process in which epithelial cells exert the 
ability to migrate and invade surrounding tissues [32]. In 
this respect, in cancer cells with AXL overexpression, 33 
genes involved in EMT were found up-regulated with a 
median fold-change of 22.7. Our findings support recent 
studies showing that AXL expression was associated with 
EMT [33-36] and in some case this phenomenon was 
driven by autocrine interactions with GAS6 produced by 
surrounding endothelial cells [10]. AXL can be activated 
through a number of different mechanisms: ligand-
dependent dimerization (principally driven by GAS6), 
ligand-independent dimerization, interaction between 
two monomers on neighbouring cells and heteromeric 
dimerization with other receptors [37-38]. We did not 
find GAS6 secretion into cell culture media suggesting 
a ligand-independent activation of AXL in our in vitro 
model. 
We finally determined the prevalence and 
clinicopathological significance of AXL and GAS6 
expression in 223 human CRC tissues. In particular, 
we showed that AXL and GAS6 overexpression is a 
molecular trait of approximately 70% of CRC with a 
different degree of expression, evaluated by IHC, with 
a statistical significant correlation between the ligand 
and receptor. Although AXL overexpression has been 
previously reported in several solid tumours [10-17] this 
significant correlation has never been reported, suggesting 
the presence of an autocrine pathway between AXL and its 
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ligand GAS6 in human CRC tissues. 
AXL and GAS6 were markedly present in less 
differentiated tumour specimens and only GAS6 was 
associated with lymph nodes status and consequently 
with tumour stage, showing a higher expression in more 
advanced disease. Neither AXL nor GAS6 had any 
apparent impact on survival, at least in our dataset. AXL 
overexpression in CRC was reported in metastatic lesion 
[39], moreover Dunne ad colleagues found that AXL was 
a strong independent negative prognostic factors in early 
stage of CRC [40].
Notably, this is the first study reporting AXL 
gene amplification in 5,4% of CRC specimens that 
overexpressed AXL protein; a significant correlation 
between AXL protein intensity and gene amplification 
was found. 
Different preclinical evidences define AXL a 
potential target to inhibit [7]. A recent report found AXL 
mutations in CRC cell lines never described before and 
many multi-kinase inhibitors blocking also AXL are under 
investigations with no specific indication for CRC [13]. 
Collectively, the results herein reported highlight 
AXL tyrosine kinase as a therapeutic target that is worth 
to be explored in a clinical setting for CRC.
MAtErIALs And MEtHods
drugs and chemicals
Foretinib was purchased from Selleck Chemicals 
(Selleckchem, Houston, TX, USA). It was dissolved 
in sterile Dimethylsulfoxide (DMSO) at 10 mM stock 
solution concentration and stored in aliquots at -20 °C. 
Working solutions were diluted in culture medium before 
each experiment and the 10 mM stock solution was stored 
at -20°C. For in vivo applications, foretinib was solubilized 
in 0.5% Tween-80 in sterile Phosphate Buffered Saline 
(PBS). 
cell lines
Human HT29, LOVO, HCT15, HCT116, COLO205 
and SW620 colorectal cancer cell lines were obtained 
from the American Type Culture Collection (ATTC) and 
have been authenticated by IRCCS “Azienda Ospedaliera 
Universitaria San Martino-IST Istituto Nazionale per 
la Ricerca sul Cancro, Genova,” Italy in 2013. The 
human SW48 (catalogue number: HTL99020), HCT116 
(catalogue number: HTL95025), SW480 (catalogue 
number: HTL99017) dimethylsulfoxide cell lines were 
obtained from IRCCS “Azienda Ospedaliera Universitaria 
San Martino-IST Istituto Nazionale per la Ricerca sul 
Cancro, Genova,” Italy. The human GEO colon cancer cell 
line was kindly provided by Dr. N. Normanno (National 
Cancer Institute, Naples, Italy). GEO-CR and SW-48 CR 
cells were established as previously described (19). GEO 
and GEO-CR cell lines were grown in DMEM (Lonza), 
supplemented with 20% fetal bovine serum (FBS; Lonza) 
and 1% penicillin/streptomycin (Lonza). SW48, SW48-
CR, LOVO, HCT15, HCT116 and SW480 cells were 
grown in RPMI- 1640 (Lonza) supplemented with 10% 
FBS and 1% penicillin/streptomycin. SW620 and HT29 
cancer cells were grown in McCoy medium (Lonza) 
supplemented with 20% FBS (Lonza) and 1% penicillin/
streptomycin (Lonza). All cell lines were grown in a 
humidified incubator with 5% of carbon dioxide (CO2) and 
95% air at 37 °C. All cell lines were routinely screened for 
the presence of mycoplasma (Mycoplasma Detection Kit; 
Roche Diagnostics).
Proliferation assay
Cell proliferation was analysed by the 
3-(4,5-dimethylthiazol-2-yl)-5-(3 carboxymethxyphenyl)-
2-(4sulfophenyl)-2H-tetrazolium (MTT) assay. Cell 
suspensions (2000 μl) containing 10000-15000 viable cells 
were plated in a 24 multiwell plate. After 24 hrs cells were 
treated with different concentrations of foretinib (0,01, 
0,1, 0,5, 1, 2, 5 and 10 μM) for 72 hrs. Each experiment 
was done in triplicate. Results represent the median of the 
three experiments, each performed in triplicate. 
Protein expression analysis
Protein lysates containing equal amount of proteins, 
measured by a modified Bradford assay (BIORAD), were 
subjected to immunoprecipitation or direct Western blot. 
Immunocomplexes were dectected with the 
enhanced chemiluminescence kit (ECL plus, Thermo 
Fisher Scientific (Rockford, IL). We used the following 
antibodies from Cell Signalling (Beverly, MA): anti-
ERK, anti-phospho-pERK(T202/Y204), anti-AKT, anti-
phospho-AKT (S473), anti-AXL, anti-phospho-AXL 
(Y702), anti-phospho-S6 ribosomal protein (S236/S253). 
Anti-α-tubulin was from Sigma (Sigma-Aldrich, St. 
Louis, MO). The following secondary antibodies from 
Bio-rad (Hercules, CA) were used: goat anti-rabbit IgG 
and rabbit anti-mouse IgG. Each experiment was done in 
triplicate. The Proteome Profiler Array has been performed 
by following manufacturer’s protocol. (Human Phospho-
Kinase Array Kit, R&D Systems). Briefly, SW620, 
SW480, LOVO and HCT116 cells were serum starved for 
24 hrs and 300 µg of protein lysates were obtained and 
incubated over night with the human phospho-kinase array 
in order to analyse the phosphorylation profile of the 41 
kinases.
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Microarray gene expression analysis of cancer cell 
lines
Agilent microarray analyses were performed to 
assess baseline gene expression profile for each cancer 
cell line using a one color labeling microarray system 
as described before [23]. Data were extracted from slide 
image using Agilent Feature Extraction software (v.10.5). 
The raw data and associated sample information were 
loaded and processed by Gene Spring® 11.5X (Agilent 
Technologies, CA, USA). For identification of genes 
significantly altered in resistant cells, total detected entities 
were filtered by signal intensity value (upper cut-off 100th 
and lower cut-off 20th percentile) and flag to remove very 
low signal entities. Data were analyzed using Student’s t 
test (p < 0.05) with a Benjamani-Hochberg multiple test 
correction to minimize selection of false positives. Of the 
significantly differentially expressed RNA, only those 
with greater than 2-fold increase or 2-fold decrease as 
compared to the controls were used for further analysis. 
Subsequently, hierarchical clustering (condition tree) was 
applied to the data files. In this way, the relationships 
between the different groups are shown. The condition 
tree was displayed as a heat map, based on expression 
levels of the probe sets. Functional and network analyses 
of statistically significant gene expression changes 
were performed using Ingenuity Pathways Analysis 
(IPA) 8.0 (Ingenuity® Systems, http://www.ingenuity.
com). Analysis considered all genes from the data set 
that met the 2-fold (p-value < 0.05) change cut-off and 
that were associated with biological functions in the 
Ingenuity Pathways Knowledge Base. The significance 
of the association between the data set and the canonical 
pathway was measured in 2 ways: 1- Ratio of the number 
of genes from the dataset that map to the pathway divided 
by the total number of genes that map to the canonical 
pathway is displayed; 2- Fisher’s exact test was used 
to calculate a p value determining the probability that 
the association between the genes in the dataset and the 
canonical pathway is explained by chance alone.
rnA interference
The small inhibitor duplex RNAs (siRNA) (ON-
target plus SMARTpool) si-Human AXL (#L-003104-00) 
was from Dharmacon (Lafayette, CO). The siCONTROL 
Non-targeting Pool (#D-001206-13-05) was used as a 
negative (scrambled) control. Cells were transfected 
with 100 nmol/L siRNAs using Dharmafect reagent 
following manufacturer’s instructions. The day before 
transfection, the cells were plated in 35 mm dishes at 40% 
of confluence in medium supplemented with 5% FBS 
without antibiotics. Cells were harvested at different time 
points (24, 48, 72 hrs) after transfection. Cell proliferation 
analysis or Western blot for AXL expression were 
performed.
Generation of stable AXL shrnA
Five lentiviral constructs (pLKO.1puro) containing 
21-mer short hairpin RNAs (shRNA) directed to various 
coding regions of AXL were kindly provided by Prof 
Rosamarina Melillo. LOVO cells were transfected with the 
pool of shAXL or with non-targeting vectors (shCTR) by 
using Fugene reagent following manufacturer’s protocol. 
Stable transfectants were selected in medium with 500ng/
mL puromycin for 12 weeks and then amplified.
Migration
Chambers of transwell (6.5 mm diameter, 8 μm 
pore size polycarbonate membrane, Corning) were used 
to evaluate the migratory capacity of shCTR cells and the 
shAXL transfected ones. A cell concentration of 50 x103 
cells in 200 μl medium without FBS was added to each 
migration (upper) chambers of transwell. Chemotaxis was 
induced by addition of 10% FBS to the medium the lower 
chamber. Cells were allowed to migrate from the upper 
compartment through the membrane towards the lower 
compartment along the chemo attractant gradient. After 
incubation for 24 hours, non-migrating cells were removed 
with cotton swabs, and the cells that migrated into the 
lower surface of the filters were stained with crystal violet. 
Growth curve
Sh-ctr cells, sh-axl pool cells and clone 1, clone 3, 
clone 5 and clone 8 were seeded with a concentration of 
50 x 10 3 at time 0 and harvested and counted after 24, 
48, 72 and 96 hrs. Each day, cells in suspension were 
harvested and stained with 0,4% trypan blue for 5 min 
at room temperature. Unstained (viable) and stained 
(nonviable) cells were counted and the percentage of dead 
cells were reported.
ELIsA assay
CRC were grown to 70% of confluence and serum-
starved for 24 hrs. GAS6 levels in culture supernatants 
were measured using a quantitative immunoassay ELISA 
kit (DuoSet ELISA Development Kit, R&D Systems). 
Samples were analysed at 450 nm with an ELISA reader 
(Model 550 microplate reader, Bio-Rad). Each experiment 
was performed in triplicate.
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Luminex
Cancer cell lines were grown to 70% of confluence 
and serum-starved for 24 hrs. TGF-β levels in supernatant 
were calculated using a Milliplex Map Kit (TGF-β single 
Plex 96-well Plate Assay Cat. #TGF-64K-019, Millipore). 
Plates were read on a Luminex 100 system.
rnA extraction and reverse transcription 
polymerase chain reaction
For the validation of genes identified by gene 
expression profiling, quantitative real-time RT–PCR was 
performed on RNA isolated from CRC cells. Total RNA 
was collected from cultured cells using the RNeasy Kit 
(Qiagen, Crawley, West Sussex, UK) according to the 
manufacturer’s instructions. Random-primed first strand 
cDNA was synthesized in a 50 μl reaction volume starting 
from 2 μg RNA by using the GeneAmp RNA PCR Core 
Kit ( AppliedBiosystems, Warringtone, UK). Quantitative 
Q-RT-PCR were performed by using SYBR Green PCR 
Master mix (Applied Byosystems) in the iCycler apparatus 
(Bio-Rad, Munich, Germany). 
The quality of RNA was verified by electrophoresis 
through 1% agarose gel and visualized with ethidium 
bromide. Primers were designed by using a software 
available at http://bioinfo.ut.ee/primer3/ and synthetized 
by the CEINGE s.c.a.r.l. DNA synthetis facility (Naples, 
Italy). To exclude DNA contamination, each PCR reaction 
was performed on untrascribed RNA. Amplification 
reactions (25 μl final reaction volume) contained 200 
nM of each primer, 3 mM MgCl2, 300 μM dNTPs, 1x 
SYBR Green PCR buffer, 0.1 U/μl AmpliTaq Gold DNA 
Polymerase, 0.1 U/μl AMP Erase, RNase-free water and 
2 μl cDNA samples. Therma cycling conditions were 
optimized for each primer pair and are available upon 
request. To verify the absence of non-specific products, 
80 cycles of melting (55 °C for 10 sec) were performed. In 
all cases, the melting curve confirmed that a single product 
was generated. Amplification was monitored by measuring 
the increase in fluorescence caused by the SYBR-Green 
binding to double-stranded DNA. Fluorescent threshold 
values were measured in triplicate and fold changes 
were calculated by the formula: 2- (sample 1 DCt – 
sample 2 DCt), where DCt is the difference between 
the amplification fluorescent thresholds of the mRNA of 
interest and the b-actin mRNA.
cell proliferation ELIsA brdu
LOVO Cells and clones suspensions (100 μl) 
containing 5000 viable cells were plated in a 96 multiwell 
plate and serum starved after 24 hour. The day after BRDU 
assay was performed following manifacturer’s instructions 
(Cell proliferation WlisaBrdu, Roche). 
tumor xenografts in nude mice
Four- to six-week-old female balb/c athymic 
(nu1/ nu1) mice were purchased from Charles River 
Laboratories. (Milan, Italy). The research protocol was 
approved and mice were maintained in accordance with 
the institutional guidelines of the Second University of 
Naples Animal Care and Use Committee. Mice were 
acclimatized at the Second University of Naples Medical 
School Animal Facility for 1 week before being injected 
with cancer cells and then caged in groups of 8. 
All studies were conducted in accordance with the 
‘Guide for the Care and Use of Laboratory Animals’ (NIH) 
and approved by the Institutional Animal Care and Used 
Committee (IACUC). 
A total of 2 x106 HCT116 cells re-suspended in 200 
μl matrigel (BD Biosciences, Milan, IT): PBS (1:1) were 
implanted subcutaneously into the right flank of nude 
female mice. Orthotopic in vivo models. The orthotopic 
implantation was performed as described by Hoffman and 
colleagues (42). After one week mice were randomized and 
divided into two different treatment groups treated with 
vehicle or foretinib (n° 8 for each group). Group 1: vehicle 
(PBS/0,5% Tween 80) was administered through oral 
gavage every day, for 5 days a week. Group 2: foretinib 
(15 mg/kg) was prepared in vehicle 1 (0.5% Tween-80 in 
sterile PBS) and administered daily through oral gavage 
for 5 days a week. Mice were treated for three weeks and 
euthanized 1 week later. The body weights were monitored 
daily. Primary tumours in the cecum were excised and 
weighed. Orthotopic implantation: subcutaneous tumours 
derived from HCT116 cells were obtained as previously 
above. When the average tumours reached a mean volume 
of 500 mm3 animals were euthanized, the tumours were 
removed using sterile technique, divided into 2-3 mm-
sized pieces, and harvested in PBS on ice. Mice were 
treated with antibiotics, ticarcillin (50 mg kg−1i.v.), two 
hours before and after tumour implantation. Animals were 
anesthetized with 2,2,2-tribomoethanol 97% TBE, Avertin 
(Sigma-Aldrich, St. Louis, MO, USA). TBE solution was 
prepared fresh daily by mixing 0.625 g of 97% crystalline 
TBE powder with 25 ml sterile 0.9% saline and then 
injected intraperitoneally at 0.01 ml/g body mass (250 
mg/kg). The abdomen was prepped with betadine solution 
and the surgical site was isolated in a sterile fashion. A 
laparotomy of 0.5 cm was conducted; the cecum was 
exteriorized and isolated using pre-cut, sterile gauze. A 
warm saline solution was used to keep the cecum wet. 
Subsequently, the cecum wall was lightly damaged and 
a single tumour fragment from HCT-116 subcutaneous 
tumours was sutured to the mesenteric border of the cecum 
wall using 6.0 nylon surgical sutures. Upon completion, 
the cecum was replaced into the abdominal cavity and 
the abdominal wound was sutured using a 6.0 Ethicon 
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absorbable stitches. (Ethicon Inc., Somerville, NJ). The 
final tumour was evaluated by caliper measurements using 
the following formula: π/6 x larger diameter x (smaller 
diameter)2. The presence of metastasis was evaluated in 
the peritoneum, liver, intestines, lungs, rectum and spleen 
and confirmed by histologic review. The tumour excised 
from each mouse was divided into 3 parts. One piece was 
formalin-fixed; the other two pieces were frozen at -80 C 
in RNAlater. Hematoxylin and eosin staining confirmed 
the presence of tumours in each sample. Student t test was 
used to evaluate the statistical significance of the results.
Patients and samples
Histological blocks of 223 patients diagnosed 
with CRC, who had undergone surgical resection 
without any preoperative treatment between 2003 and 
2011, were selected to obtain tissue microarrays upon 
informed consent. From the most representative areas of 
each donor tissue sample a single core with a diameter 
of 2 mm was arranged into one recipient paraffin block 
(3×2.5 cm) using a semiautomatic tissue arrayed (Galileo 
TMA). All cases were diagnosed at the National Cancer 
Institute Fondazione ‘G. Pascale’ of Naples and at Medical 
Oncology, Seconda Università degli Studi of Naples and 
staged according to the TNM classification (version 
dependent on year of diagnosis). Clinicopathological 
characteristics including demographics and staging 
features were evaluated.
Immunohistochemistry (IHc)
Four μm-thick sections were deparaffinized and 
rehydrated and antigen retrieve technique was carried 
out in pH 6.0 buffer in a microwave for 3 minutes using 
standard histological technique. The primary antibodies 
were incubated overnight at 4°C at the concentration 
of 10ug/mL for anti-GAS6 (AF885, Goat mAb, R&D 
Systems) and 1:300 for anti-AXL (C89E7, Rabbit mAb, 
Cell Signaling), washed and then incubated with anti-
Goat and anti-Rabbit secondary antibodies respectively. 
Appropriate positive and negative control were chosen. 
Evaluation has been done by two expert pathologists 
without prior knowledge of clinicopathological 
information (G. L; G.B). The scoring was performed 
considering percentage of tumour cells staining positively 
(positive and negative). In GAS6 positive samples, 
staining results were defined as low (1-19%) and high ( 
> = 20%). Whereas in AXL positive samples , staining 
expression levels were classified into low (1-19%) and 
high ( > = 20%) and intensity level was graded as low (1+) 
, moderate (2+) or intense (3+). Both in AXL and GAS6 
specimens 20% thresholds was chosen according with 
median scoring value obtained after statistical analysis. 
Furthermore, to better investigate AXL expression, a 
semiquantitative scale ranging from 0 to 300 based on 
histoscore (HSCORE) was obtained considering tumour 
cells staining percentage (0-100) multiplied by staining 
intensity (0-3).
FIsH analysis
Tissue array sections from paraffin-embedded 
tissue were heated for 4 h at 62°C and immediately 
deparaffinized in two rinses of 100% xylene for 10 min 
each. The slides were then treated with 0.3 M sodium 
chloride and 0.03 M sodium citrate for 20 min at 80°C, 
and with 0.05 mg/ml proteinase for 10 min at 37°C. AXL/
CEN19q FISH Probe ( FG0088 ABNOVA) (10 ml) was 
applied to the tissue sections and covered with a coverslip. 
Both probe and target DNA were simultaneously 
denatured at 85°C for 5 min and incubated overnight at 
37°C using the Hybrite System. Post-hybridization washes 
were performed according to the ‘rapid wash protocol’ 
provided by Vysis. Slides were counterstained with 
406-diamidino-2-phenylindole 2HCl (DAPI). FISH was 
performed according to the manufacturer’s instructions 
(Vysis). FISH data were collected using an Olympus 
BX 61 fluorescence microscope equipped with a cooled 
black-and-white camera controlled by the associated 
software (Olympus, Italy). Signals were evaluated by 
two independent evaluators (GL, GB) scoring at least 60 
interphase nuclei in four different high power fields (HPF). 
The FISH results were scored as follow: specimens with 
the ratio AXL/CEN19 ≥ 2.0 were considered as amplified; 
polysomic were considered cases showing three or more 
CEP-19 signals per cell in more than 30% of the evaluated 
cells.
statistical analysis
The Student’s t test was used to evaluate the 
statistical significance of differences between treatment 
effects of in vivo and in vitro data. Differences 
between categorical data were measured by χ2 square 
test. Differences between continuous variables were 
investigated by the Mann-Whitney U test and Kruskal-
Wallis test, when appropriate. Survival curves were plotted 
using the Kaplan-Meier method and compared using the 
Log-rank test. All the tests were two-sided, with p value 
of < 0.05 considered to indicate statistical significance. 
All statistical analyses were carried out using the SPSS 
package (version 21.0 for Windows, SPSS Inc., USA).
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